Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28078725 | 0.98 | TSHR (0.62) | TSHRLMNAKDM4EKMT2AHSD17B10 | |
| SCHEMBL7674738 | 0.93 | TSHR (0.56) | TSHRLMNAKDM4EKMT2AHSD17B10 | |
| SCHEMBL1403588 | 0.91 | TSHR (0.61) | TSHRLMNAKDM4EKMT2AALDH1A1 | |
| SCHEMBL1233167 | 0.91 | TSHR (0.68) | TSHRLMNAKDM4EKMT2AHSD17B10 | |
| SCHEMBL644646 | 0.89 | TSHR (0.45) | TSHRALDH1A1DGAT1CA12CA14 | |
| SCHEMBL31364348 | 0.89 | TSHR (0.58) | TSHRLMNAKMT2AALDH1A1DGAT1 | |
| SCHEMBL28731518 | 0.89 | TSHR (0.58) | TSHRLMNAKMT2AALDH1A1DGAT1 | |
| SCHEMBL20151961 | 0.89 | TSHR (0.58) | TSHRLMNAKMT2AALDH1A1DGAT1 | |
| SCHEMBL3987825 | 0.89 | TSHR (0.58) | TSHRLMNAKMT2AALDH1A1DGAT1 | |
| SCHEMBL31364345 | 0.89 | TSHR (0.58) | TSHRLMNAKMT2AALDH1A1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| WO-2023137446-A1 | PRODRUGS OF 3,4-METHYLENEDIOXY- N-ETHYL-AMPHETAMINE (MDEA) AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| CN-105503882-B | The method for preparing S1P1 receptor modulators and its crystal form | 艾尼纳制药公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-105051038-B | Biaryl-propanoic derivatives and its purposes as drug | 赛诺菲 | 2018-08-03 | — | — | CN | disclosed |
| US-10034861-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-07-31 | — | — | US | disclosed |
| EP-3083261-B1 | LASER MARKABLE LAMINATES AND DOCUMENTS | AGFA-GEVAERT (BE) | 2018-02-21 | — | — | EP | disclosed |
| US-20180000786-A1 | 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2018-01-04 | — | — | US | disclosed |
| US-9776445-B2 | Colour laser markable articles | AGFA-GEVAERT (BE) | 2017-10-03 | — | — | US | disclosed |
| US-9776445-B2 | Colour laser markable articles | AGFA-GEVAERT (BE) | 2017-10-03 | — | — | US | disclosed |
| US-20170275241-A1 | TRANSESTERIFICATION REACTION BY MEANS OF IRON CATALYST | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2017-09-28 | — | — | US | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1358174-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| US-6610730-B2 | Viricides; protease inbhibitor | AGOURON PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| WO-2002057248-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| US-6365572-B1 | FOR THERAPY OF DISEASES RELATED TO INCREASED OR UNWANTED SYNTHESIS OF BASEMENT MEMBRANES SUCH AS DIABETES MELLITUS; ATHEROSCLEROSIS; CANCER; DIABETIC RETINOPATHIA; FIBROPLASIA RETROLENTALIS; OR PSORIASIS, RHEUMATOIC ARTHRITIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-02 | — | — | US | disclosed |
| CN-1342167-A | Low molecular weight peptide derivatives as inhibitors of laminin/nidogen interaction | AVENTIS PHARMA GMBH (DE) | 2002-03-27 | — | — | CN | disclosed |
| EP-1157040-A1 | LOW MOLECULAR WEIGHT PEPTIDE DERIVATIVES AS INHIBITORS OF THE LAMININ/NIDOGEN INTERACTION | Aventis Pharma Deutschland GmbH (DE) | 2001-11-28 | — | — | EP | disclosed |
| EP-1070727-A1 | Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction | Aventis Pharma Deutschland GmbH (DE) | 2001-01-24 | — | — | EP | disclosed |
| WO-2000052051-A1 | LOW MOLECULAR WEIGHT PEPTIDE DERIVATIVES AS INHIBITORS OF THE LAMININ/NIDOGEN INTERACTION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-09-08 | — | — | WO | disclosed |
| EP-0650970-A1 | Bisketene derivatives and process for production and use thereof | Tidwell, Thomas T. (CA) | 1995-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10034861-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE3A, PDE5A, PDE12 | TSHR 2941/4885LMNA 2936/4885KDM4E 1008/4885 |
| US-20170275241-A1 | TRANSESTERIFICATION REACTION BY MEANS OF IRON CATALYST | FASN, TECR, CYP4F3 | TSHR 945/4885LMNA 1148/4885KDM4E 2505/4885 |
| US-20180000786-A1 | 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | PDE3A, PDE5A, PDE12 | TSHR 2941/4885LMNA 2936/4885KDM4E 1008/4885 |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | TSHR 3128/4885LMNA 2804/4885KDM4E 4215/4885 |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CLPP, PRCP, PREP | TSHR 3820/4885LMNA 364/4885KDM4E 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.